NCT03018405: A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

NCT03018405
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patient with a tumor metastasis in the central nervous system
https://ClinicalTrials.gov/show/NCT03018405

Comments are closed.

Up ↑